



Contact:

For MaxCyte, Inc.:

Karen A. Donato, Ph.D.
Executive Vice President
Sales and Marketing
(301) 944-1700

For CCS Cell Culture Service:

Susan Friedemann
Sales & Communication
+49 (40) 471 96 575

Richard Field
COO North America
(732) 329 2355

For Immediate Release

CCS Cell Culture Service GmbH Acquires the MaxCyte® STX™ Scalable Transfection System for Cell Line Development

Gaithersburg, MD, and Hamburg, Germany, May 11, 2010 –MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, is pleased to announce that CCS Cell Culture Service GmbH has acquired the MaxCyte® STX™ Scalable Transfection System to develop and optimize cells for the pharmaceutical industry.

“The MaxCyte STX represents a fast, simple, and scalable way to transfect cell lines, primary cells, and stem cells with high efficiency and performance for cell-based assays for screening ion channels, GPCRs, and other targets,” says Dr. Oliver Klotzsche, Managing Director and co-founder of CCS. “The MaxCyte STX will help CCS expand its catalogue of cell-based products to pharmaceutical companies involved in drug discovery. By producing specific and customized cells faster and with higher efficiency, we can help our customers achieve their goals to develop assays and screen their compound libraries faster, resulting in more opportunities to find successful drug candidates.”

“MaxCyte is very pleased that CCS has acquired the MaxCyte STX to expand the range of cells that it can provide for drug discovery,” states Douglas Doerfler, President and CEO at MaxCyte. “CCS is known around the world for providing high quality cell-based products to the pharmaceutical industry. Adding the MaxCyte STX to its production capabilities, CCS will enable its pharmaceutical customers to develop more physiologically relevant assays that seamlessly scale up to high throughput screening volumes, saving time and improving the effectiveness of drug discovery programs.”

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte designed the MaxCyte® STX™ Scalable Transfection System for the rapid development and consistent production of (co)transfected primary cells, stem cells, and cell lines for cell-based screening assays for ion channels, GPCRs, and other targets, with comparable results and Seamless Scalability™ from the bench to HTS scale.

For more information, <http://www.maxcyte.com/cell-based-screening.shtml>.

About CCS Cell Culture Service

CCS is dedicated to improving the output of drug discovery research by providing custom made cell based reagents. For more than ten years, CCS has been supporting the research departments of pharmaceutical and biotechnology companies in their efforts to discover new drug entities. Originally established as a general provider of research services, CCS has advanced to become a custom supplier of recombinant cell lines, assay-ready frozen cells, qualified membranes and proteins for high-throughput-screening. Major pharmaceutical companies all over Europe and the USA now rely on the custom products and services of CCS.

For more information, <http://www.cellcultureservice.com>